StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) bonds

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.69+0.06 (+0.90%)

Close on Nov 17, 2026Market cap $441.88MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$156.74M
Long-term debt
Net debt
$111.57M
After $45.17M of cash
Implied interest rate
14.72%
FY2025 interest ÷ average debt
Interest coverage
-1.7×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Evolus's 10-Q for the period ended Jun 30, 2026

Evolus's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawn
A&R Loan Agreement, Tranche Three$50.00M–
A&R Loan Agreement, Tranche Two$50.00M–
New Pharmakon Term Loans$250.00M$150.00M
New Pharmakon Term Loans––
Prior Pharmakon Loan Agreement$125.00K$125.00M
Revolving Credit Facility$30.00M$10.00M

See a number that looks wrong?